Cytokinetics Share Price Today
(NASDAQ: CYTK)

Name: Cytokinetics Share Price Today (NASDAQ: CYTK) - Cytokinetics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Cytokinetics share price is $39.48 & ₹3,374.16 as on 18 Apr 2025, 2.30 'hrs' IST

$39.48

▲

0.33

(0.84%)

Market is closed - opens 7 PM, 21 Apr 2025

View live Cytokinetics share price in Dollar and Rupees. Guide to invest in Cytokinetics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Cytokinetics, along with analyst recommendations, forecasts, and comprehensive financials.

Cytokinetics share price movements

Today's Low: $38.47
Today's High: $39.50
$39.48
2.57%
Downside
Day's Volatility :2.62%
Upside
0.05%
52 Weeks Low: $32.74
52 Weeks High: $68.76
$39.48
17.07%
Downside
52 Weeks Volatility :52.39%
Upside
42.58%

Cytokinetics (CYTK) Returns

Period	Cytokinetics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-13.84%	-2.8%	0.0%
6 Months	-26.63%	-11.0%	0.0%
1 Year	-41.55%	-1.9%	0.0%
3 Years	7.87%	-1.5%	-12.9%

Cytokinetics (CYTK) Key Statistics

in dollars & INR

Previous Close	$39.15
Open	$38.77
Today's High	$39.5
Today's Low	$38.465
Market Capitalization	$4.7B
Today's Volume	$1.1M
52 Week High	$68.76
52 Week Low	$32.74
Revenue TTM	$18.5M
EBITDA	$-526.7M
Earnings Per Share (EPS)	$-5.26
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-572.15%

How to invest in Cytokinetics Stock (CYTK) from India?

It is very easy for Indian residents to invest directly in Cytokinetics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cytokinetics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cytokinetics or CYTK on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cytokinetics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cytokinetics shares which would translate to 0.022 fractional shares of Cytokinetics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cytokinetics, in just a few clicks!

Returns in Cytokinetics (CYTK) for Indian investors in Rupees

The Cytokinetics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Cytokinetics investment value today

Current value as on today

₹60,787

Returns

₹39,213

(-39.21%)

Returns from Cytokinetics Stock

₹41,554 (-41.55%)

Dollar Returns

₹2,341 (+2.34%)

Indian investors sentiment towards Cytokinetics (CYTK)

309%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Search interest for Cytokinetics Stock from India on INDmoney has increased by 309% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Cytokinetics

BlackRock Inc
12.98%
Vanguard Group Inc
10.00%
FMR Inc
9.06%
T. Rowe Price Investment Management,Inc.
9.02%
Wellington Management Company LLP
6.62%
State Street Corp
5.17%

Analyst Recommendation on Cytokinetics

Rating

Trend

Buy

84%Buy

16%Hold

0%Sell

Based on 25 Wall street analysts offering stock ratings for Cytokinetics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Cytokinetics Stock (CYTK)

What analysts predicted

Upside of 98.33%

Target:

$78.30

Current:

$39.48

Insights on Cytokinetics Stock (Ticker Symbol: CYTK)

Price Movement
In the last 1 year, CYTK stock has moved down by -42.0%
Increasing Revenue
Revenue is up for the last 3 quarters, 249.0K → 16.92M (in $), with an average increase of 71.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -160.54M → -150.02M (in $), with an average increase of 7.0% per quarter
CYTK vs ONC (1 yr)
In the last 1 year, Beone Medicines Ltd has given 76.1% return, outperforming this stock by 118.1%
CYTK vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 28.9% return, outperforming this stock by 25.7%
Price to Sales
ForCYTK every $1 of sales, investors are willing to pay $239.3, whereas for Beone Medicines Ltd, the investors are paying $6.4 for every $1 of sales.

Cytokinetics Technicals Summary

Sell

Neutral

Buy

Cytokinetics is currently in a neutral trading position according to technical analysis indicators.

Cytokinetics (CYTK) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cytokinetics Inc	-8.4%	-26.63%	-41.55%	7.87%	154.55%
Regeneron Pharmaceuticals, Inc.	-17.1%	-41.85%	-37.2%	-21.74%	-0.85%
Beone Medicines Ltd	-13.12%	5.03%	78.34%	40.23%	43.44%
Vertex Pharmaceuticals Incorporated	-4.76%	2.3%	24.05%	71.43%	78.99%
Alnylam Pharmaceuticals, Inc.	-9.09%	-19.67%	62.43%	39.66%	61.91%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cytokinetics Inc	NA	NA	-0.42	-5.62	-5.72	-0.3	NA	-1.14
Regeneron Pharmaceuticals, Inc.	14.68	14.68	0.9	41.18	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.09	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.34	17.96	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.81	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cytokinetics Inc	Buy	$4.7B	154.55%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$60.5B	-0.85%	14.68	31.07%
Beone Medicines Ltd	NA	$26.9B	43.44%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$125.7B	78.99%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$30.4B	61.91%	NA	-12.37%

Cytokinetics Dividend announcements

Cytokinetics Earnings
Cytokinetics’s price-to-earnings ratio stands at None

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Organization	Cytokinetics
Employees	498
CEO	Mr. Robert I. Blum
Industry	Health Technology

Management People of Cytokinetics

Name	Title
Mr. Robert I. Blum	CEO, President & Director
Dr. Fady Ibraham Malik FACC, M.D., Ph.D.	Executive Vice President of Research & Development
Mr. Andrew M. Callos	Executive VP & Chief Commercial Officer
Dr. James A. Spudich Ph.D.	Co-Founder & Member of Scientific Advisory Board
Mr. Jeff Lotz	Vice President of Sales & Operations
Ms. Holly Laughlin	VP of Accounting & Corporate Controller
Mr. Matt Yang	Vice President of Corporate Finance and Financial Planning & Analysis
Mr. Steven M. Cook J.D.	Senior Vice President of Global Supply Chain Operations & Technical Operations
Ms. Kari K. Loeser J.D.	VP & Chief Compliance Officer
Mr. Scott R. Jordan	Senior Vice President of Global Marketing & Commercial Strategy

Important FAQs about investing in CYTK Stock from India :

What is Cytokinetics share price today?

Cytokinetics share price today stands at $39.48, Open: $38.77 ; Previous Close: $39.15 ; High: $39.50 ; Low: $38.47 ; 52 Week High: $68.76 ; 52 Week Low: $32.74.

The stock opens at $38.77, after a previous close of $39.15. The stock reached a daily high of $39.50 and a low of $38.47, with a 52-week high of $68.76 and a 52-week low of $32.74.

Can Indians buy Cytokinetics shares?

Yes, Indians can invest in the Cytokinetics (CYTK) from India.

With INDmoney, you can buy Cytokinetics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Cytokinetics at zero transaction cost.

How can I buy Cytokinetics shares from India?

It is very easy to buy Cytokinetics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cytokinetics (CYTK) be purchased?

Yes, you can buy fractional shares of Cytokinetics with INDmoney app.

What are the documents required to start investing in Cytokinetics stocks?

To start investing in Cytokinetics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.